AIM:NYE-AIM ImmunoTech Inc (USD)

COMMON STOCK | Biotechnology | NYE

Last Closing Price

USD 0.99

Change

-0.01 (-0.53)%

Market Cap

USD 0.05B

Volume

0.09M

Avg Analyst Target

N/A

Avg User Target

USD
Average Analyst Rating

N/A

Fundamental Analysis

Verdict


AIM ImmunoTech Inc (AIM) Stock Analysis:
Based on the AIM ImmunoTech Inc stock forecasts from 0 analysts, the average analyst target price for AIM ImmunoTech Inc is not available over the next 12 months. AIM ImmunoTech Inc’s average analyst rating is not available. Stock Target Advisor’s own stock analysis of AIM ImmunoTech Inc is Slightly Bullish , which is based on 5 positive signals and 4 negative signals. At the last closing, AIM ImmunoTech Inc’s stock price was USD 0.99. AIM ImmunoTech Inc’s stock price has changed by -4.37% over the past week, -2.48% over the past month and -51.00% over the last year.

About

AIM ImmunoTech Inc., an immuno-pharma company, focuses on the research and development of therapeutics to treat multiple types of cancers, viral diseases, and immune-deficiency disorders in the United States. The company's products include Ampligen, a drug of macromolecular ribon ...Read More

Technical Indicators

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2022-05-16 )

Largest Industry Peers for Biotechnology

Symbol Name Price(Change) Market Cap Price / Earning Ratio EV/EBITDA
NVO Novo Nordisk A/S

-2.80 (-2.64%)

USD250.18B 34.29 3.53
BHVN Biohaven Pharmaceutical Holdin..

-0.40 (-0.28%)

USD10.02B N/A N/A
DNA Ginkgo Bioworks Holdings

-0.23 (-8.65%)

USD4.72B N/A N/A
RCUS Arcus Biosciences Inc

+0.42 (+2.17%)

USD1.39B 27.28 3.74
MYOV Myovant Sciences Ltd

+0.68 (+7.38%)

USD0.83B N/A N/A
ADCT ADC Therapeutics SA

-0.25 (-3.38%)

USD0.57B -99,999.99 N/A
SIGA SIGA Technologies Inc

-0.10 (-1.34%)

USD0.54B 8.22 4.44
PFNX Pfenex Inc

N/A

USD0.44B 268.67 63.90
ZYME Zymeworks Inc

-0.21 (-3.78%)

USD0.32B 300.20 N/A
LCTX Lineage Cell Therapeutics Inc

+0.03 (+2.68%)

USD0.19B 3.63 N/A

ETFs Containing AIM

Symbol Name Weight Mer Price(Change) Market Cap

N/A

Market Performance

  Market Performance vs.
Industry/Classification (Biotechnology)
Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 7.07% 97% A+ 88% B+
Dividend Return N/A N/A N/A N/A N/A
Total Return 7.07% 97% A+ 87% B+
Trailing 12 Months  
Capital Gain -51.00% 61% D- 9% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -51.00% 61% D- 8% F
Trailing 5 Years  
Capital Gain N/A N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return N/A N/A N/A N/A N/A
Average Annual (5 Year Horizon)  
Capital Gain 24.80% 61% D- 85% B
Dividend Return N/A N/A N/A N/A N/A
Total Return 24.80% 61% D- 84% B
Risk Return Profile  
Volatility (Standard Deviation) 98.45% 21% F 7% F
Risk Adjusted Return 25.19% 54% F 33% F
Market Capitalization 0.05B 35% F 11% F
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 87%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Key Financial Ratios

  Ratio vs. Industry/Classification
(Biotechnology)
Ratio vs. Market
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio 1.35 69% D+ 98% A+
Price/Book Ratio 0.82 84% B 80% B-
Price / Cash Flow Ratio -3.40 52% F 84% B
EV/EBITDA 0.07 83% B 97% A+
Management Effectiveness  
Return on Equity -32.37% 81% B- 8% F
Return on Invested Capital -68.71% 42% F 3% F
Return on Assets -17.44% 81% B- 3% F
Debt to Equity Ratio N/A N/A N/A N/A N/A
Technical Ratios  
Dividend Yield N/A N/A N/A N/A N/A
Short Ratio 0.84 81% B- 72% C-
Short Percent 1.94% 61% D- 65% D
Beta -0.63 96% A 98% A+
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Ratings

Target Price Action Rating Action Analyst Rating Price Date

No discussions yet

User / Independent Analyst Ratings

User Name Target Rating Target Horizon (Months) Target Price User Analysis Date Comment

Fundamental Analysis Breakdown

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Underpriced compared to book value

The stock is trading low compared to its peers on a price to book value basis and is in the top quartile. It may be underpriced but do check its financial performance to make sure there is no specific reason.

Superior return on equity

The company management has delivered better return on equity in the most recent 4 quarters than its peers, placing it in the top quartile.

Superior return on assets

The company management has delivered better return on assets in the most recent 4 quarters than its peers, placing it in the top quartile.

Positive free cash flow

The company had positive total free cash flow in the most recent four quarters.

Underpriced on free cash flow basis

The stock is trading low compared to its peers on a price to free cash flow basis and is in the top quartile. It may be underpriced but do check its financial performance to make sure there is no specific reason.

What to not like:
Low market capitalization

This is among the smaller entities in its sectors with below median market capitalization. That may make it less stable in the long run unless it has a unique technology or market which can help it grow or get acquired in future.

High volatility

The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.

Negative cashflow

The company had negative total cash flow in the most recent four quarters.

Low Earnings Growth

This stock has shown below median earnings growth in the previous 5 years compared to its sector